Lung cancer is the most common malignancy across world. The new era in lung treatments, especially this past decade, has yielded novel categories of targeted therapy for specific mutations and adjuvant therapy, both which have led to improved survival rates. In present study, we review changes development with a special focus on using tyrosine kinase inhibitors (TKIs) administered non-small-cel...

In the past decades, lung cancer is considered one of lethal cancers all across world due to its evidenced greatest mortality and morbidity. Currently, main clinical treatment methods for involve surgery, chemotherapy, radiotherapy, anti-angiogenesis inhibitors tyrosine kinase inhibitors. field anticancer drugs, a variety new drugs have been emerging in recent years. They include chemotherapy w...

Driver tyrosine kinase mutations are rare in sarcomas, and patterns of tyrosine phosphorylation are poorly understood. To better understand the signaling pathways active in sarcoma, we examined global tyrosine phosphorylation in sarcoma cell lines and human tumor samples. Anti-phosphotyrosine antibodies were used to purify tyrosine phosphorylated peptides, which were then identified by liquid c...

Tyrphostins, a series of compounds with hydroxy cis-cinnamonitrile backbone structures, are used as protein tyrosine kinase inhibitors to study signal transduction. While studying the inhibition of pp60c-src protein tyrosine kinase activity with tyrphostins 23 and 25 (3,4-di- and 3,4,5-trihydroxy cis-cinnamonitrile), we found the inhibitors to be quite unstable. The inhibition of pp60c-src acti...

ALK gene missense mutations are conventionally considered non-driver without pathological significance, and therefore, there is a lack of effective target drugs against them. The standard treatment option for patients with chemotherapy or antiangiogenic agents, which usually results in unsatisfactory outcomes. Herein, we present the case patient metastatic lung adenocarcinoma harboring only mut...

Precision (target) medicine is proposed as a new strategy to identify and develop highly selective drugs against specific targets for the disease more precise tailoring of medicines target populations patients. can be an important approach create novel safer therapeutics (tyrosine kinase inhibitors, tumour monoclonal antibodies) patients with gene mutation, aberrations, or protein over-expressi...

Acrosome reaction (AR) is an exocytotic process of fundamental importance for the spermatozoon to fertilize the oocyte. The mechanisms mediating this process are only partially defined. The aim of the present study was to investigate the role of various kinases and the extracellular signal-regulated kinase (ERK) pathway in the induction of the AR and associated phosphorylation of tyrosine (Tyr)...

Targeting anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase receptor initially identified as a potent oncogenic driver in anaplastic large-cell lymphoma (ALCL) in the form of nucleophosmin (NPM)-ALK fusion protein, using tyrosine kinase inhibitors has shown to be a promising therapeutic approach for ALK-expressing tumors. However, clinical resistance to ALK inhibitors invariably occu...

AIMS To define the molecular mechanisms of cardiotoxicity induced by Sunitinib and to identify the role of biological sex in modulating toxicity. METHODS AND RESULTS Exposure of isolated cardiomyocytes to plasma-relevant concentrations of Sunitinib and other tyrosine kinase inhibitors produces a broad spectrum of abnormalities and cell death via apoptosis downstream of sexually dimorphic kina...